Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis
M Etemadifar, H Nouri, M Pitzalis, ML Idda… - Journal of Neurology …, 2022 - jnnp.bmj.com
Studies among people with multiple sclerosis (pwMS) receiving disease-modifying therapies
(DMTs) have provided adequate evidence for an appraisal of COVID-19 vaccination policies …
(DMTs) have provided adequate evidence for an appraisal of COVID-19 vaccination policies …
Safety of COVID-19 vaccines: spotlight on neurological complications
G Tondo, E Virgilio, A Naldi, A Bianchi, C Comi - Life, 2022 - mdpi.com
The COVID-19 pandemic has led to unprecedented demand on the global healthcare
system. Remarkably, at the end of 2021, COVID-19 vaccines received approvals for human …
system. Remarkably, at the end of 2021, COVID-19 vaccines received approvals for human …
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in …
Background In this study we aimed to monitor the risk of breakthrough SARS-CoV-2
infection in patients with MS (pwMS) under different DMTs and to identify correlates of …
infection in patients with MS (pwMS) under different DMTs and to identify correlates of …
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
I Schiavetti, C Cordioli, ML Stromillo… - Multiple Sclerosis …, 2022 - journals.sagepub.com
Background: Patients with multiple sclerosis (pwMS) treated with anti-CD20 or fingolimod
showed a reduced humoral response to SARS-CoV-2 vaccines. Objective: In this study we …
showed a reduced humoral response to SARS-CoV-2 vaccines. Objective: In this study we …
Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies
L Prosperini, C Tortorella, S Haggiag, S Ruggieri… - Journal of …, 2022 - Springer
Objective To identify risk factors for an increased lethality of COVID-19 in patients with
multiple sclerosis (MS). Methods We searched scientific databases to identify cohort studies …
multiple sclerosis (MS). Methods We searched scientific databases to identify cohort studies …
The value of Interferon β in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review
G Bellucci, A Albanese, C Rizzi, V Rinaldi… - Frontiers in …, 2023 - frontiersin.org
Interferon-beta (IFN-β) for Multiple Sclerosis (MS) is turning 30. The COVID-19 pandemic
rejuvenated the interest in interferon biology in health and disease, opening translational …
rejuvenated the interest in interferon biology in health and disease, opening translational …
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
TE Smith, M Madhavan, D Gratch, A Patel… - Multiple Sclerosis and …, 2022 - Elsevier
Background The risk of SARS-CoV-2 infection and severity with disease modifying therapies
(DMTs) in multiple sclerosis (MS) remains unclear, with some studies demonstrating …
(DMTs) in multiple sclerosis (MS) remains unclear, with some studies demonstrating …
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study
N Frahm, F Fneish, D Ellenberger, J Haas… - The Lancet Regional …, 2022 - thelancet.com
Background Vaccines offer people with multiple sclerosis (PwMS) an effective protection
against severe COVID-19 disease courses. However, representative real-world data on the …
against severe COVID-19 disease courses. However, representative real-world data on the …
Cellular and humoral immunity to SARS‐CoV‐2 infection in multiple sclerosis patients on ocrelizumab and other disease‐modifying therapies: a multi‐ethnic …
I Kister, Y Patskovsky, R Curtin, J Pei… - Annals of …, 2022 - Wiley Online Library
Objective The objective of this study was to determine the impact of multiple sclerosis (MS)
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity …
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity …
Longitudinal postvaccine SARS-CoV-2 immunoglobulin G titers, memory B-cell responses, and risk of COVID-19 in multiple sclerosis over 1 year
G Disanto, A Galante, M Cantu', R Sacco… - Neurology …, 2022 - AAN Enterprises
Background and Objectives Some disease-modifying treatments impair response to severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in multiple sclerosis …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in multiple sclerosis …